Brett Monia, Ionis Pharmaceuticals CEO
Ionis presents pivotal rare disease data, builds toward first solo launch: #ACC24
As Ionis gears up to launch its first wholly-owned medicine, researchers fleshed out its Phase 3 success in a rare genetic disease Sunday morning.
The California-based company expanded on the pivotal trial win for olezarsen, which hit its primary endpoint in September. In the new data presented at the annual American College of Cardiology meeting, Ionis said olezarsen at the 80 mg dose lowered triglyceride levels by a placebo-adjusted 44% after six months, good for a p-value of p<0.001.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
